Literature DB >> 24106109

A dual-responsive mesoporous silica nanoparticle for tumor-triggered targeting drug delivery.

Dong Xiao1, Hui-Zhen Jia, Jing Zhang, Chen-Wei Liu, Ren-Xi Zhuo, Xian-Zheng Zhang.   

Abstract

A novel pH- and redox- dual-responsive tumor-triggered targeting mesoporous silica nanoparticle (TTTMSN) is designed as a drug carrier. The peptide RGDFFFFC is anchored on the surface of mesoporous silica nanoparticles via disulfide bonds, which are redox-responsive, as a gatekeeper as well as a tumor-targeting ligand. PEGylated technology is employed to protect the anchored peptide ligands. The peptide and monomethoxypolyethylene glycol (MPEG) with benzoic-imine bond, which is pH-sensitive, are then connected via "click" chemistry to obtain TTTMSN. In vitro cell research demonstrates that the targeting property of TTTMSN is switched off in normal tissues with neutral pH condition, and switched on in tumor tissues with acidic pH condition after removing the MPEG segment by hydrolysis of benzoic-imine bond under acidic conditions. After deshielding of the MPEG segment, the drug-loaded nanoparticles are easily taken up by tumor cells due to the exposed peptide targeting ligand, and subsequently the redox signal glutathione in tumor cells induces rapid drug release intracellularly after the cleavage of disulfide bond. This novel intelligent TTTMSN drug delivery system has great potential for cancer therapy.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  drug delivery; pH-responsive; peptides; redox-responsive; tumor-triggered target

Mesh:

Substances:

Year:  2013        PMID: 24106109     DOI: 10.1002/smll.201301926

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  23 in total

Review 1.  Applications of nanomaterials as vaccine adjuvants.

Authors:  Motao Zhu; Rongfu Wang; Guangjun Nie
Journal:  Hum Vaccin Immunother       Date:  2014-11-17       Impact factor: 3.452

Review 2.  Nanotechnology: Future of Oncotherapy.

Authors:  Kshipra M Gharpure; Sherry Y Wu; Chun Li; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Clin Cancer Res       Date:  2015-07-15       Impact factor: 12.531

3.  Real-Time Monitoring of ATP-Responsive Drug Release Using Mesoporous-Silica-Coated Multicolor Upconversion Nanoparticles.

Authors:  Jinping Lai; Birju P Shah; Yixiao Zhang; Letao Yang; Ki-Bum Lee
Journal:  ACS Nano       Date:  2015-04-15       Impact factor: 15.881

Review 4.  Mesoporous silica nanoparticles in nanomedicine applications.

Authors:  Miguel Manzano; María Vallet-Regí
Journal:  J Mater Sci Mater Med       Date:  2018-05-08       Impact factor: 3.896

5.  Dual-responsive nanoparticles release cargo upon exposure to matrix metalloproteinase and reactive oxygen species.

Authors:  Kevin B Daniel; Cassandra E Callmann; Nathan C Gianneschi; Seth M Cohen
Journal:  Chem Commun (Camb)       Date:  2016-02-04       Impact factor: 6.222

Review 6.  Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?

Authors:  María Vallet-Regí; Ferdi Schüth; Daniel Lozano; Montserrat Colilla; Miguel Manzano
Journal:  Chem Soc Rev       Date:  2022-07-04       Impact factor: 60.615

7.  Stimuli-Responsive Programmed Specific Targeting in Nanomedicine.

Authors:  Sheng Wang; Peng Huang; Xiaoyuan Chen
Journal:  ACS Nano       Date:  2016-02-16       Impact factor: 15.881

8.  Hierarchical Targeting Strategy for Enhanced Tumor Tissue Accumulation/Retention and Cellular Internalization.

Authors:  Sheng Wang; Peng Huang; Xiaoyuan Chen
Journal:  Adv Mater       Date:  2016-06-03       Impact factor: 30.849

Review 9.  Nanoarchitectured prototypes of mesoporous silica nanoparticles for innovative biomedical applications.

Authors:  Ranjith Kumar Kankala; Ya-Hui Han; Hong-Ying Xia; Shi-Bin Wang; Ai-Zheng Chen
Journal:  J Nanobiotechnology       Date:  2022-03-12       Impact factor: 10.435

10.  Development of docetaxel nanocrystals surface modified with transferrin for tumor targeting.

Authors:  Jin-Seok Choi; Jeong-Sook Park
Journal:  Drug Des Devel Ther       Date:  2016-12-16       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.